AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

Companies with late-stage RNA and oligonucleotide drugs

19 companies hold rights to 20 RNA and oligonucleotide drugs (siRNA, antisense, mRNA and other oligonucleotide drugs) that are in Phase 3, Phase 2/3 or filed for approval. Sorted by the number of such drugs, then by name. Approved drugs are not counted. The full directory, with financials, is on the companies page.

BiologicsSmall moleculesCell and gene therapiesRNA and oligonucleotide drugsPeptide drugs
Late-stage RNA and oligonucleotide drugs, by developer
CompanyTickerLate-stageDrugs (stage, indications)
Ionis PharmaceuticalsIONS6Elsunersen (Phase 3, Epilepsy); Obudanersen (Phase 3, Angelman Syndrome); Pelacarsen (Phase 3, Atherosclerotic Cardiovascular Disease); Sefaxersen (Phase 3, IgA Nephropathy); Ulefnersen (Phase 3, Amyotrophic Lateral Sclerosis); Volanesorsen (Phase 3, Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia)
Alnylam PharmaceuticalsALNY4ALN-CIDEB (Phase 3, MASH / NASH); Cemdisiran (Phase 3, Age-Related Macular Degeneration, Myasthenia Gravis, Generalized Myasthenia Gravis); Nucresiran (Phase 3, Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy); Zilebesiran (Phase 3, Hypertension)
NovartisNVS4Delpacibart braxlosiran (Phase 3, Facioscapulohumeral Muscular Dystrophy); Delpacibart etedesiran (Phase 3, Myotonic Dystrophy Type 1); NIO752 (Phase 3, Alzheimer's Disease, Progressive Supranuclear Palsy); Pelacarsen (Phase 3, Atherosclerotic Cardiovascular Disease)
Arrowhead PharmaceuticalsARWR3Fazirsiran (Phase 3, Alpha-1 Antitrypsin Deficiency); Olpasiran (Phase 3, Atherosclerotic Cardiovascular Disease); Zodasiran (Phase 3, Homozygous Familial Hypercholesterolemia)
Regeneron PharmaceuticalsREGN2ALN-CIDEB (Phase 3, MASH / NASH); Cemdisiran (Phase 3, Age-Related Macular Degeneration, Myasthenia Gravis, Generalized Myasthenia Gravis)
RocheRHHBY2Sefaxersen (Phase 3, IgA Nephropathy); Zilebesiran (Phase 3, Hypertension)
AmgenAMGN1Olpasiran (Phase 3, Atherosclerotic Cardiovascular Disease)
BiogenBIIB1Zorevunersen (Phase 3, Dravet Syndrome)
CSPC Pharmaceutical Group10931SYH2053 (Phase 3, Atherosclerotic Cardiovascular Disease)
Dicerna Pharmaceuticals, Inc.—1Lepodisiran (Phase 3, Atherosclerotic Cardiovascular Disease)
Eli LillyLLY1Lepodisiran (Phase 3, Atherosclerotic Cardiovascular Disease)
Otsuka Holdings45781Ulefnersen (Phase 3, Amyotrophic Lateral Sclerosis)
Praxis Precision Medicines, Inc.PRAX1Elsunersen (Phase 3, Epilepsy)
PTC TherapeuticsPTCT1Volanesorsen (Phase 3, Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia)
Qilu Pharmaceutical—1QLC7401 (Phase 3, Atherosclerotic Cardiovascular Disease)
Stoke Therapeutics, Inc.STOK1Zorevunersen (Phase 3, Dravet Syndrome)
Suzhou Ribo Life Science69381QLC7401 (Phase 3, Atherosclerotic Cardiovascular Disease)
Swedish Orphan Biovitrum AB (publ)SOBI1Volanesorsen (Phase 3, Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia)
Takeda Pharmaceutical CompanyTAK1Fazirsiran (Phase 3, Alpha-1 Antitrypsin Deficiency)

Stage is the furthest stage the drug has reached in any indication. Kind follows each drug's recorded modality; a drug whose modality is not recorded is left out.